Baird Financial Group Inc. Has $1.69 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Baird Financial Group Inc. grew its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 7.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 56,129 shares of the biopharmaceutical company’s stock after purchasing an additional 3,947 shares during the quarter. Baird Financial Group Inc.’s holdings in TG Therapeutics were worth $1,689,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock valued at $469,454,000 after purchasing an additional 209,190 shares during the last quarter. Clearbridge Investments LLC bought a new position in shares of TG Therapeutics in the 4th quarter valued at about $55,237,000. Northern Trust Corp boosted its stake in shares of TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock valued at $46,141,000 after purchasing an additional 120,785 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of TG Therapeutics by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock valued at $38,212,000 after purchasing an additional 84,904 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of TG Therapeutics by 1.2% in the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company’s stock valued at $27,985,000 after purchasing an additional 10,989 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $34.99 on Tuesday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market capitalization of $5.56 billion, a P/E ratio of -349.87 and a beta of 2.21. The company’s 50 day moving average price is $38.90 and its two-hundred day moving average price is $33.79. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business’s quarterly revenue was up 90.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.07) earnings per share. On average, analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TGTX. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.